AZ Alliance Bolsters Daiichi’s US Primary Care Presence
This article was originally published in PharmAsia News
Daiichi Sankyo is moving to shore up its generic-threatened primary care business in the US through a co-promotion deal with AstraZeneca for a novel constipation drug.
You may also be interested in...
FDA approval of the first oral form of Valeant’s mu-opioid receptor antagonist Relistor will pit the franchise against Movantik for the treatment of patients with opioid-induced constipation with non-cancer pain.
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.